Status:
COMPLETED
Biologically Focused Therapy of Treatment-Refractory MDS Patients
Lead Sponsor:
Stanford University
Collaborating Sponsors:
Notable Labs Inc.
Conditions:
Myelodysplastic Syndromes
Eligibility:
All Genders
18+ years
Brief Summary
This non interventional study examines the feasibility of using patient specific therapeutic screening method, ex vivo to enhance current treatment recommendations in a clinically feasible time frame ...
Detailed Description
This study utilizes the Notable Labs personalized testing service using an ex vivo assay, but does not involve actual treatment or treatment determinations. The results of these screenings will be mad...
Eligibility Criteria
Inclusion
- Provide informed consent;
- Myelodysplastic syndrome as defined by WHO classification (see Appendix 2), or MDS/MPN with \>= 5% blasts in the bone marrow or peripheral blood, including chronic myelomonocytic leukemia (CMML) 1 and 2 by WHO classification
- Relapsed/refractory disease, defined as failed or are ineligible for hypomethylating agent therapy
- Cytogenetics reported
Exclusion
- Hypoplastic MDS
- Patients without adequate marrow samples for ex vivo analysis
Key Trial Info
Start Date :
February 18 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2022
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT05245032
Start Date
February 18 2020
End Date
December 1 2022
Last Update
March 14 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford MDS Center
Stanford, California, United States, 94304